Continuous glucose monitoring for hyperglycemia in critically ill patients: a randomized controlled trial
Abstract
BACKGROUND
Continuous glucose monitors (CGM) could potentially improve management of hyperglycemia compared to standard point of care glucose monitoring for critically ill patients. However, there is limited evidence to support routine use of CGM in the intensive care unit.
RESEARCH QUESTION
In critically ill patients with hyperglycemia, do CGM improve time within target glucose range compared to standard of care?
STUDY DESIGN AND METHODS
This was an investigator-initiated, single-center, parallel-group, open-label, randomized controlled trial. Adult patients admitted to a medical or surgical intensive care unit, who had diabetes mellitus or hyperglycemia, and were treated with insulin were eligible for enrollment. Participants were randomly assigned to have glucose monitoring performed with CGM (intervention group) or standard of care (control group). Groups were compared for glycemic control and other relevant outcomes. The primary outcome for the study was percentage of time within the normoglycemic range, defined as 70-180 mg/dL (3.9-10 mmol/L).
RESULTS
Eighty-five participants were enrolled and randomized to study groups with 43 participants in the intervention (CGM) group and 42 patients in the control (standard of care) group. For the primary outcome, there was no statistically significant difference between the intervention group (mean = 60.5%, SD = 30.5) and the control group (mean = 61.4%, SD = 28.3) in time within the goal glucose range (mean difference -0.9%, 95%…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 43 participants or records.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.